The Peptide NewsroomPeptide research, industry and supply-chain headlines

Hims and Hers Launches Five Compounded Peptide Treatments With No FDA-Approved Formulations

Topic card: safety

Hims & Hers Health has introduced five compounded peptide and longevity treatments in the United States through a new Peptides+ telehealth platform. None of the company's specific compounded formulations has FDA approval.

The starting lineup is sermorelin, glutathione, nicotinamide adenine dinucleotide (NAD+), vitamin B-12 and L-carnitine. Sermorelin stimulates growth hormone release, glutathione is an antioxidant associated with cellular protection, NAD+ supports cellular metabolism, B-12 contributes to red blood cell production and nerve function, and L-carnitine helps the body convert fat into energy.

The demand is already there

A company spokesperson said more than 10,000 people joined the early-access waiting list within 15 days of its launch in late October. Hims said the products are manufactured by licensed US pharmacies subject to state pharmacy board oversight, describing those facilities as adhering to "rigorous quality standards."

The process starts with an assessment of medical history, current medications and health goals, with independent licensed providers determining eligibility and dosage. Chief Medical Officer Dr. Anant Vinjamoori said people with serious cardiovascular, liver or kidney disease would not qualify at this stage.

What the company admits it does not know

The most useful line in the whole announcement comes from Hims itself. "We don't have all of this data that we're used to having with compounds like this," Vinjamoori told CNBC, adding that follow-up could involve dose adjustments, alternative compounds or referrals elsewhere.

That candor is worth noting, and it sits awkwardly next to the plan to add BPC-157 and TB-500. Both are unapproved, both are marketed for healing and soft-tissue recovery, and much of the available research on them has involved animals rather than human participants.

Researchers push back on dosing

Joshua Kritzer, a chemistry professor at Tufts University, said peptides should be viewed "the same way you would view any drug that hasn't been rigorously tested," and that anecdotal reports are "just not enough information to put a substance in your body."

Paul Knoepfler of UC Davis Health went at the dosing question directly, saying "the dosing for these products really has not been established" and warning that excessive exposure to synthetic peptides could trigger unexpected immune reactions.

Bottom line

Hims is betting that physician oversight and licensed compounding pharmacies close the gap that clinical trials have not. The researchers quoted say the gap is dosing, and nobody in this story claims it has been settled.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: safety

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Karnataka Regulators Cancel a Bengaluru Peptide Party as India's Longevity Market Accelerates

Karnataka's drug regulator canceled a Bengaluru "Peptide Party" on August 29 and questioned the organizers about ingredients, legality and health claims. The Indian Express reports the shutdown against a biohacking market Grand View Research valued at $1.21 billion in 2025.

Engineered ICOSL Peptide Cuts Proteinuria in Mice, But No Human Trials Yet

Researchers engineered a 19-amino-acid peptide from inducible co-stimulator ligand that blocks alpha-v-beta-3 integrin on kidney podocytes, reducing urinary protein across several rodent models. The work is entirely preclinical, tested a single dose, and human trials have not begun.

Hims & Hers Launches Peptides+ Longevity Platform Nationwide, But No Trial Data Comes With It

Hims & Hers has rolled out Peptides+, a compounded peptide and nutrient longevity program sold through its telehealth platform with at-home blood collection. The commercial logic is clear, but the announcement carries no trial data on any of the five named compounds.